| Dr William B Bossert, MD | |
|
755 Norland Ave, Ste 101, Chambersburg, PA 17201-4221 | |
| (717) 262-2665 | |
| (717) 267-0159 |
| Full Name | Dr William B Bossert |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 14 Years |
| Location | 755 Norland Ave, Chambersburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780974022 | NPI | - | NPPES |
| 103024869 | Medicaid | PA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chambersburg Hospital | Chambersburg, PA | Hospital |
| Waynesboro Hospital | Waynesboro, PA | Hospital |
| Gettysburg Hospital | Gettysburg, PA | Hospital |
| Milton S Hershey Medical Center | Hershey, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellspan Medical Group | 1951213115 | 1946 |
News Archive
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it has completed its previously announced underwritten public offering of American Depositary Shares at a price to the public of $7.60 per ADS.
iMedicor and Transgenomic today announced that they have signed an agreement to develop an educational marketing program for NuroPro, Transgenomic's diagnostic tests for Alzheimer's and Parkinson's disease.
Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough.
Influenza outbreaks were shorter and resulted in fewer cases and fewer deaths at long-term care facilities that started residents on preventive antiviral medications within five days of the first case, compared to those that started later, according to a new study in the July 1 issue of Clinical Infectious Diseases, currently available online.
The July edition of SLAS Discovery is a Special Edition featuring the cover article, "Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry" by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).
› Verified 3 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it has completed its previously announced underwritten public offering of American Depositary Shares at a price to the public of $7.60 per ADS.
iMedicor and Transgenomic today announced that they have signed an agreement to develop an educational marketing program for NuroPro, Transgenomic's diagnostic tests for Alzheimer's and Parkinson's disease.
Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough.
Influenza outbreaks were shorter and resulted in fewer cases and fewer deaths at long-term care facilities that started residents on preventive antiviral medications within five days of the first case, compared to those that started later, according to a new study in the July 1 issue of Clinical Infectious Diseases, currently available online.
The July edition of SLAS Discovery is a Special Edition featuring the cover article, "Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry" by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William B Bossert, MD 3421 Concord Rd, York, PA 17402-9001 Ph: (717) 262-2665 | Dr William B Bossert, MD 755 Norland Ave, Ste 101, Chambersburg, PA 17201-4221 Ph: (717) 262-2665 |
News Archive
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it has completed its previously announced underwritten public offering of American Depositary Shares at a price to the public of $7.60 per ADS.
iMedicor and Transgenomic today announced that they have signed an agreement to develop an educational marketing program for NuroPro, Transgenomic's diagnostic tests for Alzheimer's and Parkinson's disease.
Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough.
Influenza outbreaks were shorter and resulted in fewer cases and fewer deaths at long-term care facilities that started residents on preventive antiviral medications within five days of the first case, compared to those that started later, according to a new study in the July 1 issue of Clinical Infectious Diseases, currently available online.
The July edition of SLAS Discovery is a Special Edition featuring the cover article, "Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry" by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).
› Verified 3 days ago
Dr. Abhishek Nitturkar, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 110 Chambers Hill Dr, Chambersburg, PA 17201 Phone: 717-709-7930 Fax: 717-709-7931 | |
Zeeshan Faruqui, MBBS Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 100 Chambers Hill Dr Ste 200, Chambersburg, PA 17201 Phone: 717-709-7930 Fax: 717-709-7931 | |
Cinda Anne Liggon, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 38 Black Ave, Suite 2, Chambersburg, PA 17201 Phone: 717-496-8521 Fax: 717-307-3487 | |
Khatuna Gurgenashvili, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 22 St Paul Dr, Chambersburg, PA 17201 Phone: 301-797-9240 Fax: 301-797-0008 | |
Dr. Syyeda Fouzia Syed, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 176 S. Coldbrook Avenue, Chambersburg, PA 17201 Phone: 717-267-7480 Fax: 717-217-4216 | |
Dana Lynn Crites, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 426 Phoenix Dr, Chambersburg, PA 17201 Phone: 717-263-7160 | |
Dr. Ruediger Kratz, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 755 Norland Ave, Suite 101, Chambersburg, PA 17201 Phone: 855-480-7553 Fax: 717-267-0159 |